GB002

· GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GB002, covering 2023-11-07 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]